Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 2 Trial of Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma

Next Previous
Trial Profile

A Randomized, Open-label, Phase 2 Trial of Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; Tucidinostat (Primary) ; Brentuximab vedotin; Carboplatin; Doxorubicin; Etoposide; Gemcitabine; Ifosfamide; Vinorelbine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use

Most Recent Events

  • 26 Aug 2024 Planned number of patients changed from 60 to 100.
  • 09 Jun 2024 Planned End Date changed from 15 May 2027 to 1 Jun 2027.
  • 09 Jun 2024 Planned primary completion date changed from 15 May 2026 to 1 Jun 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top